Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced the Company will be presenting esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer’s 35th Anniversary Annual Meeting, being held November 9-14, 2020 virtually.
October 15, 2020
· 4 min read